The vector of anti-EGFRvIII chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human EGFRvIII. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-EGFRvIII antibody, two CD137 (4-1BB) signaling domains, an FKBP and FRB dimerizer-binding pair, and a CD3-zeta signaling domain. The activation of conditional CAR can be controlled by FKBP-FRB dimerization using rapamycin. And the vector product was designed for the treatment of glioblastoma.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
|VP-CAR-LC547||Lenti-EGFRvIII CAR (scFv-41BB-CD3ζ, 139) Viral Particle|
|VP-CAR-LC715||Lenti-EGFRvIII CAR (scFv-CD28-41BB-CD3ζ, MR1) Viral Particle|
|VP-CAR-LC696||Lenti-EGFRvIII CAR (scFv-CD28-41BB-CD3ζ, 139) Viral Particle|
|CAR-LC243||Anti-EGFRvIII (MR1) h(CD28-41BB-CD3ζ) CAR, pCDCAR1|
|VP-CAR-LC714||Lenti-EGFRvIII CAR (scFv--CD28-CD3ζ, MR1) Viral Particle|
|CAR-LC272||Anti-EGFRvIII (139) h(41BB-CD3ζ, FKBP/FRB) Conditional CAR, pCDCAR1|
|CAR-LC222||Anti-EGFRvIII (139) h(CD28-CD3ζ) CAR, pCDCAR1|
|CAR-LC242||Anti-EGFRvIII (MR1) h(-CD28-CD3ζ) CAR, pCDCAR1|
|CAR-LC221||Anti-EGFRvIII (139) h(CD28-41BB-CD3ζ) CAR, pCDCAR1|
|CAR-LC379||Anti-EGFRvIII h(CD28-41BB-CD3ζ, CD70) Armoured CAR, pCDCAR1|
Copyright © 2007 - 2018 Creative Biolabs. All Rights Reserved